|Dr. Gary S. Jacob||CEO & Non-Exec. Director||N/A||N/A||1947|
|Mr. Peter Anastasiou||Exec. Vice Chairman||N/A||N/A||1960|
|Dr. Jerry Kanellos Ph.D.||Chief Operating Officer||N/A||N/A||1961|
|Mr. Phillip Allen Hains||CFO & Company Sec.||N/A||N/A||1959|
|Mr. David Lyon||Head of Marketing||N/A||N/A||N/A|
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease; and IMM-529, a clinical stage product for clostridium difficile infections. The company has a research collaboration with the United States Department of Defense to develop and clinically evaluate a therapeutic against campylobacter. Immuron Limited was founded in 1994 and is based in Carlton South, Australia.
Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.